RxDoctor Payments Data

Rick Sessions, PA

Surgical · Sarasota, FLNPI 1780634949

Payments from drug & device makers

$4,696in general payments, 2019–2025

Across 210 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$514
  • Pfizer$368
  • Medtronic$331
  • Bayer$303
  • Incyte Corporation$215
  • Johnson & Johnson$190
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$4,696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,696 in reported general payments places this provider in the 90th percentile of 1,018 surgical providers in Florida.

See all surgical providers in Florida

Medicare billing

Part B allowed, 2024
$220,427
Medicare patients
656
Services billed
4,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron92$87,502
GemtesaVibegron33$36,885
Tamsulosin Hcl623$6,211
Testosterone Cypionate151$6,059
Solifenacin Succinate90$4,770
Oxybutynin Chloride ErOxybutynin Chloride182$2,111
Methenamine Hippurate41$2,029
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst72$1,825
NitrofurantoinNitrofurantoin Macrocrystal43$1,685
Ciprofloxacin Hcl171$899
Finasteride85$862
Alfuzosin Hcl ErAlfuzosin Hcl26$410
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$262
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$154
Diazepam13$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$87,50292 claims
Sumitomo Pharma America, Inc.Gemtesa$34$36,88533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,018 surgical providers in Florida.

Other surgical in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →